NO861643L - Nye 8-fenylxantiner og fremgangsmaate for deres fremstilling. - Google Patents
Nye 8-fenylxantiner og fremgangsmaate for deres fremstilling.Info
- Publication number
- NO861643L NO861643L NO861643A NO861643A NO861643L NO 861643 L NO861643 L NO 861643L NO 861643 A NO861643 A NO 861643A NO 861643 A NO861643 A NO 861643A NO 861643 L NO861643 L NO 861643L
- Authority
- NO
- Norway
- Prior art keywords
- compound
- formula
- tetrahydro
- purin
- dioxo
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 52
- 238000002360 preparation method Methods 0.000 title description 44
- 150000001875 compounds Chemical class 0.000 claims description 162
- -1 nitro, amino Chemical group 0.000 claims description 48
- 150000003839 salts Chemical class 0.000 claims description 46
- 239000012453 solvate Substances 0.000 claims description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 239000001301 oxygen Substances 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000005499 phosphonyl group Chemical group 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 239000011593 sulfur Substances 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 125000005907 alkyl ester group Chemical group 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims description 4
- 239000007800 oxidant agent Substances 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000004450 alkenylene group Chemical group 0.000 claims description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Chemical group C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 3
- 150000007860 aryl ester derivatives Chemical class 0.000 claims description 3
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 claims description 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- JVYMKTAPCLSXLC-UHFFFAOYSA-N COClO Chemical compound COClO JVYMKTAPCLSXLC-UHFFFAOYSA-N 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000005133 alkynyloxy group Chemical group 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 40
- 238000004458 analytical method Methods 0.000 description 29
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 22
- 238000002844 melting Methods 0.000 description 20
- 230000008018 melting Effects 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 17
- 235000013985 cinnamic acid Nutrition 0.000 description 17
- 229930016911 cinnamic acid Natural products 0.000 description 17
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 17
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 15
- 239000007787 solid Substances 0.000 description 14
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 13
- 229960005305 adenosine Drugs 0.000 description 13
- 239000005557 antagonist Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000000825 pharmaceutical preparation Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 229960000583 acetic acid Drugs 0.000 description 10
- 238000007363 ring formation reaction Methods 0.000 description 10
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000001991 pathophysiological effect Effects 0.000 description 9
- 230000002378 acidificating effect Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000011321 prophylaxis Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 239000012362 glacial acetic acid Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- LBOUHDMYVURTMA-AATRIKPKSA-N (e)-3-(4-formylphenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=C(C=O)C=C1 LBOUHDMYVURTMA-AATRIKPKSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- BLTGSBVSJOCCTK-VMPITWQZSA-N (e)-3-[4-(1,3-dimethyl-2,6-dioxo-7h-purin-8-yl)phenyl]prop-2-enoic acid Chemical compound N1C=2C(=O)N(C)C(=O)N(C)C=2N=C1C1=CC=C(\C=C\C(O)=O)C=C1 BLTGSBVSJOCCTK-VMPITWQZSA-N 0.000 description 5
- ACCCXSZCOGNLFL-UHFFFAOYSA-N 8-phenyl-3,7-dihydropurine-2,6-dione Chemical class N1C=2C(=O)NC(=O)NC=2N=C1C1=CC=CC=C1 ACCCXSZCOGNLFL-UHFFFAOYSA-N 0.000 description 5
- 206010003671 Atrioventricular Block Diseases 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- 229960000278 theophylline Drugs 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 208000010271 Heart Block Diseases 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 description 4
- 238000007086 side reaction Methods 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 3
- 102000009346 Adenosine receptors Human genes 0.000 description 3
- 108050000203 Adenosine receptors Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102000000033 Purinergic Receptors Human genes 0.000 description 3
- 108010080192 Purinergic Receptors Proteins 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000003405 ileum Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 150000004682 monohydrates Chemical class 0.000 description 3
- WHQSYGRFZMUQGQ-UHFFFAOYSA-N n,n-dimethylformamide;hydrate Chemical compound O.CN(C)C=O WHQSYGRFZMUQGQ-UHFFFAOYSA-N 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000006798 ring closing metathesis reaction Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 description 2
- NQZJYXQDYMWLRV-DTQAZKPQSA-N (e)-3-[4-(1,3-dibenzyl-2,6-dioxo-7h-purin-8-yl)phenyl]prop-2-enoic acid Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1C(N1)=NC2=C1C(=O)N(CC=1C=CC=CC=1)C(=O)N2CC1=CC=CC=C1 NQZJYXQDYMWLRV-DTQAZKPQSA-N 0.000 description 2
- VEBGGRQCTLTELZ-JLHYYAGUSA-N (e)-3-[4-(1-benzyl-2,6-dioxo-3-propyl-7h-purin-8-yl)phenyl]prop-2-enoic acid Chemical compound O=C1N(CCC)C=2NC(C=3C=CC(\C=C\C(O)=O)=CC=3)=NC=2C(=O)N1CC1=CC=CC=C1 VEBGGRQCTLTELZ-JLHYYAGUSA-N 0.000 description 2
- FEQOPACWPQFLSM-RMKNXTFCSA-N (e)-3-[4-(1-ethyl-3-methyl-2,6-dioxo-7h-purin-8-yl)phenyl]prop-2-enoic acid Chemical compound N=1C=2C(=O)N(CC)C(=O)N(C)C=2NC=1C1=CC=C(\C=C\C(O)=O)C=C1 FEQOPACWPQFLSM-RMKNXTFCSA-N 0.000 description 2
- WOKYOQJTERQUGM-RMKNXTFCSA-N (e)-3-[4-(1-methyl-2,6-dioxo-3-propyl-7h-purin-8-yl)phenyl]prop-2-enoic acid Chemical compound N=1C=2C(=O)N(C)C(=O)N(CCC)C=2NC=1C1=CC=C(\C=C\C(O)=O)C=C1 WOKYOQJTERQUGM-RMKNXTFCSA-N 0.000 description 2
- UGCOFEOEBHUEHA-JXMROGBWSA-N (e)-3-[4-(2,6-dioxo-1,3-dipropyl-7h-purin-8-yl)phenyl]prop-2-enoic acid Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(\C=C\C(O)=O)C=C1 UGCOFEOEBHUEHA-JXMROGBWSA-N 0.000 description 2
- BPUHAALOTSSBQJ-VMPITWQZSA-N (e)-3-[4-(2,6-dioxo-3-propyl-7h-purin-8-yl)phenyl]prop-2-enoic acid Chemical compound N=1C=2C(=O)NC(=O)N(CCC)C=2NC=1C1=CC=C(\C=C\C(O)=O)C=C1 BPUHAALOTSSBQJ-VMPITWQZSA-N 0.000 description 2
- TUQGJOHJGMPIKR-VMPITWQZSA-N (e)-3-[4-(3-ethyl-2,6-dioxo-7h-purin-8-yl)phenyl]prop-2-enoic acid Chemical compound N=1C=2C(=O)NC(=O)N(CC)C=2NC=1C1=CC=C(\C=C\C(O)=O)C=C1 TUQGJOHJGMPIKR-VMPITWQZSA-N 0.000 description 2
- AUVHWQDPENFZCL-RMKNXTFCSA-N (e)-3-[4-(3-methyl-2,6-dioxo-1-propyl-7h-purin-8-yl)phenyl]prop-2-enoic acid Chemical compound N=1C=2C(=O)N(CCC)C(=O)N(C)C=2NC=1C1=CC=C(\C=C\C(O)=O)C=C1 AUVHWQDPENFZCL-RMKNXTFCSA-N 0.000 description 2
- CTFIDLHWESNGMD-QPJJXVBHSA-N (e)-3-[4-(3-methyl-2,6-dioxo-7h-purin-8-yl)phenyl]prop-2-enoic acid Chemical compound N=1C=2C(=O)NC(=O)N(C)C=2NC=1C1=CC=C(\C=C\C(O)=O)C=C1 CTFIDLHWESNGMD-QPJJXVBHSA-N 0.000 description 2
- DHINCXPFWWHQGY-RMKNXTFCSA-N (e)-3-[4-[1-methyl-3-(2-methylpropyl)-2,6-dioxo-7h-purin-8-yl]phenyl]prop-2-enoic acid Chemical compound N1C=2C(=O)N(C)C(=O)N(CC(C)C)C=2N=C1C1=CC=C(\C=C\C(O)=O)C=C1 DHINCXPFWWHQGY-RMKNXTFCSA-N 0.000 description 2
- GJRFVRIHEZCVCK-VMPITWQZSA-N (e)-3-[4-[3-(2-methylpropyl)-2,6-dioxo-7h-purin-8-yl]phenyl]prop-2-enoic acid Chemical compound N1C=2C(=O)NC(=O)N(CC(C)C)C=2N=C1C1=CC=C(\C=C\C(O)=O)C=C1 GJRFVRIHEZCVCK-VMPITWQZSA-N 0.000 description 2
- QMHUDUFZLSWSOZ-UHFFFAOYSA-N 3-[4-(2,6-dioxo-1,3-dipropyl-7h-purin-8-yl)phenyl]prop-2-ynoic acid Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(C#CC(O)=O)C=C1 QMHUDUFZLSWSOZ-UHFFFAOYSA-N 0.000 description 2
- FNLDCZCNGSQKIC-UHFFFAOYSA-N 5,6-diamino-1,3-dimethylpyrimidine-2,4-dione;hydrate Chemical compound O.CN1C(N)=C(N)C(=O)N(C)C1=O FNLDCZCNGSQKIC-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ZGSDJMADBJCNPN-UHFFFAOYSA-N [S-][NH3+] Chemical compound [S-][NH3+] ZGSDJMADBJCNPN-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- BIXYYZIIJIXVFW-UUOKFMHZSA-N (2R,3R,4S,5R)-2-(6-amino-2-chloro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O BIXYYZIIJIXVFW-UUOKFMHZSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- HWJBOIMFFUDOEJ-FMIVXFBMSA-N (e)-3-[4-(1,3-dibutyl-2,6-dioxo-7h-purin-8-yl)phenyl]prop-2-enoic acid Chemical compound N1C=2C(=O)N(CCCC)C(=O)N(CCCC)C=2N=C1C1=CC=C(\C=C\C(O)=O)C=C1 HWJBOIMFFUDOEJ-FMIVXFBMSA-N 0.000 description 1
- KXLNQJJYBBNCJB-JXMROGBWSA-N (e)-3-[4-(1,3-diethyl-2,6-dioxo-7h-purin-8-yl)phenyl]prop-2-enoic acid Chemical compound N=1C=2C(=O)N(CC)C(=O)N(CC)C=2NC=1C1=CC=C(\C=C\C(O)=O)C=C1 KXLNQJJYBBNCJB-JXMROGBWSA-N 0.000 description 1
- IVZGNEYSRNZBTA-FMIVXFBMSA-N (e)-3-[4-(3-benzyl-1-methyl-2,6-dioxo-7h-purin-8-yl)phenyl]prop-2-enoic acid Chemical compound C1=2N=C(C=3C=CC(\C=C\C(O)=O)=CC=3)NC=2C(=O)N(C)C(=O)N1CC1=CC=CC=C1 IVZGNEYSRNZBTA-FMIVXFBMSA-N 0.000 description 1
- YSJXOUKDQBKGPH-JLHYYAGUSA-N (e)-3-[4-(3-benzyl-2,6-dioxo-1-propyl-7h-purin-8-yl)phenyl]prop-2-enoic acid Chemical compound C1=2NC(C=3C=CC(\C=C\C(O)=O)=CC=3)=NC=2C(=O)N(CCC)C(=O)N1CC1=CC=CC=C1 YSJXOUKDQBKGPH-JLHYYAGUSA-N 0.000 description 1
- BQOSAZORIXERQY-DHZHZOJOSA-N (e)-3-[4-[1-[(4-cyanophenyl)methyl]-3-methyl-2,6-dioxo-7h-purin-8-yl]phenyl]prop-2-enoic acid Chemical compound O=C1N(C)C=2NC(C=3C=CC(\C=C\C(O)=O)=CC=3)=NC=2C(=O)N1CC1=CC=C(C#N)C=C1 BQOSAZORIXERQY-DHZHZOJOSA-N 0.000 description 1
- LEFXGHXQNVVYNF-JXMROGBWSA-N (e)-3-[4-[3-[(3-cyanophenyl)methyl]-1-methyl-2,6-dioxo-7h-purin-8-yl]phenyl]prop-2-enoic acid Chemical compound C1=2NC(C=3C=CC(\C=C\C(O)=O)=CC=3)=NC=2C(=O)N(C)C(=O)N1CC1=CC=CC(C#N)=C1 LEFXGHXQNVVYNF-JXMROGBWSA-N 0.000 description 1
- ZYVYEJXMYBUCMN-UHFFFAOYSA-N 1-methoxy-2-methylpropane Chemical compound COCC(C)C ZYVYEJXMYBUCMN-UHFFFAOYSA-N 0.000 description 1
- QVHNPERSEFABEH-UHFFFAOYSA-N 2,2-dibromopropanoic acid Chemical compound CC(Br)(Br)C(O)=O QVHNPERSEFABEH-UHFFFAOYSA-N 0.000 description 1
- YCWRFIYBUQBHJI-UHFFFAOYSA-N 2-(4-aminophenyl)acetonitrile Chemical group NC1=CC=C(CC#N)C=C1 YCWRFIYBUQBHJI-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NZAHVUIIMFOCDF-UHFFFAOYSA-N 4-[(4-amino-3-methyl-2,6-dioxopyrimidin-1-yl)methyl]benzonitrile Chemical compound O=C1N(C)C(N)=CC(=O)N1CC1=CC=C(C#N)C=C1 NZAHVUIIMFOCDF-UHFFFAOYSA-N 0.000 description 1
- COOZZYZLMSQUTR-UHFFFAOYSA-N 4-[(4-amino-3-methyl-5-nitroso-2,6-dioxo-1,3-diazinan-1-yl)methyl]benzonitrile Chemical compound O=C1N(C)C(N)C(N=O)C(=O)N1CC1=CC=C(C#N)C=C1 COOZZYZLMSQUTR-UHFFFAOYSA-N 0.000 description 1
- MQNBKOLISSZYQM-UHFFFAOYSA-N 4-[(6-amino-3-methyl-2,4-dioxopyrimidin-1-yl)methyl]benzonitrile Chemical compound O=C1N(C)C(=O)C=C(N)N1CC1=CC=C(C#N)C=C1 MQNBKOLISSZYQM-UHFFFAOYSA-N 0.000 description 1
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 1
- WWPPZPCNZGXBFF-UHFFFAOYSA-N 5,6-diamino-1,3-dimethyl-2-sulfanylidenepyrimidin-4-one Chemical compound CN1C(N)=C(N)C(=O)N(C)C1=S WWPPZPCNZGXBFF-UHFFFAOYSA-N 0.000 description 1
- PTMILWDITIQZMO-UHFFFAOYSA-N 5,6-diamino-1-methyl-3-propylpyrimidine-2,4-dione Chemical compound CCCN1C(=O)C(N)=C(N)N(C)C1=O PTMILWDITIQZMO-UHFFFAOYSA-N 0.000 description 1
- OIHHBESCFLISMR-UHFFFAOYSA-N 6-amino-1-methyl-3-propylpyrimidine-2,4-dione Chemical compound CCCN1C(=O)C=C(N)N(C)C1=O OIHHBESCFLISMR-UHFFFAOYSA-N 0.000 description 1
- VMNWYLSOJUGKAC-UHFFFAOYSA-N 6-amino-1-methyl-5-nitroso-3-propylpyrimidine-2,4-dione Chemical compound CCCN1C(=O)C(N=O)=C(N)N(C)C1=O VMNWYLSOJUGKAC-UHFFFAOYSA-N 0.000 description 1
- GZLZRPNUDBIQBM-UHFFFAOYSA-N 6-amino-1-methylpyrimidine-2,4-dione Chemical compound CN1C(N)=CC(=O)NC1=O GZLZRPNUDBIQBM-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 239000012839 Krebs-Henseleit buffer Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- UYJXRRSPUVSSMN-UHFFFAOYSA-P ammonium sulfide Chemical compound [NH4+].[NH4+].[S-2] UYJXRRSPUVSSMN-UHFFFAOYSA-P 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- QYMFNZIUDRQRSA-UHFFFAOYSA-N dimethyl butanedioate;dimethyl hexanedioate;dimethyl pentanedioate Chemical compound COC(=O)CCC(=O)OC.COC(=O)CCCC(=O)OC.COC(=O)CCCCC(=O)OC QYMFNZIUDRQRSA-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- ZQHFILHFNHMKLT-FMIVXFBMSA-N ethyl (e)-3-[4-(2,6-dioxo-1,3-dipropyl-7h-purin-8-yl)phenyl]prop-2-enoate Chemical compound N=1C=2C(=O)N(CCC)C(=O)N(CCC)C=2NC=1C1=CC=C(\C=C\C(=O)OCC)C=C1 ZQHFILHFNHMKLT-FMIVXFBMSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000005248 left atrial appendage Anatomy 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- UDGSVBYJWHOHNN-UHFFFAOYSA-N n',n'-diethylethane-1,2-diamine Chemical compound CCN(CC)CCN UDGSVBYJWHOHNN-UHFFFAOYSA-N 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000649 purine antagonist Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000005247 right atrial appendage Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/20—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB858510758A GB8510758D0 (en) | 1985-04-27 | 1985-04-27 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO861643L true NO861643L (no) | 1986-10-28 |
Family
ID=10578311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO861643A NO861643L (no) | 1985-04-27 | 1986-04-25 | Nye 8-fenylxantiner og fremgangsmaate for deres fremstilling. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US4879296A (es) |
| EP (1) | EP0203721B1 (es) |
| JP (1) | JPH0788381B2 (es) |
| KR (1) | KR860008176A (es) |
| AP (1) | AP22A (es) |
| AT (1) | ATE77088T1 (es) |
| AU (1) | AU581507B2 (es) |
| CA (1) | CA1286666C (es) |
| DE (1) | DE3685608T2 (es) |
| DK (1) | DK169271B1 (es) |
| ES (1) | ES8800945A1 (es) |
| FI (1) | FI861750A (es) |
| GB (1) | GB8510758D0 (es) |
| GR (1) | GR861107B (es) |
| HU (1) | HUT41027A (es) |
| IE (1) | IE60022B1 (es) |
| IL (1) | IL78605A (es) |
| MC (1) | MC1743A1 (es) |
| NO (1) | NO861643L (es) |
| NZ (1) | NZ215948A (es) |
| PT (1) | PT82451B (es) |
| ZA (1) | ZA863132B (es) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4710503A (en) * | 1985-02-07 | 1987-12-01 | Euroceltique S.A. | 6-thioxanthine derivatives |
| GB8510758D0 (en) * | 1985-04-27 | 1985-06-05 | Wellcome Found | Compounds |
| GB8610136D0 (en) * | 1986-04-25 | 1986-05-29 | Wellcome Found | Compounds |
| AT388500B (de) * | 1987-10-27 | 1989-06-26 | Wellcome Found | Antivirale 8-phenylxanthine |
| US5310916A (en) * | 1988-07-19 | 1994-05-10 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Trifunctional agents useful as irreversible inhibitors of A1-adenosine receptors |
| US5298508A (en) * | 1988-07-19 | 1994-03-29 | The United States Of America As Represented By The Department Of Health And Human Services | Irreversible inhibitors of adenosine receptors |
| AU5436790A (en) * | 1989-04-19 | 1990-11-16 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Sulfer-containing xanthine derivatives as adenosin antagonists |
| WO1991016056A1 (en) * | 1990-04-16 | 1991-10-31 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Use of purinergic receptor agonists as antineoplastic agents |
| DE4129603A1 (de) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| CA2082325A1 (en) * | 1991-11-08 | 1993-05-09 | Fumio Suzuki | Xanthine derivatives |
| US5336769A (en) * | 1992-02-17 | 1994-08-09 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
| US5484920A (en) * | 1992-04-08 | 1996-01-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for Parkinson's disease |
| US5300298A (en) * | 1992-05-06 | 1994-04-05 | The Pennsylvania Research Corporation | Methods of treating obesity with purine related compounds |
| TW252044B (es) * | 1992-08-10 | 1995-07-21 | Boehringer Ingelheim Kg | |
| JP2613355B2 (ja) * | 1992-09-28 | 1997-05-28 | 協和醗酵工業株式会社 | パーキンソン氏病治療剤 |
| CA2112031A1 (en) * | 1992-12-24 | 1994-06-25 | Fumio Suzuki | Xanthine derivatives |
| US5521315A (en) * | 1993-01-12 | 1996-05-28 | Cell Therapeutics, Inc. | Olefin substituted long chain compounds |
| WO1994025462A1 (en) * | 1993-05-03 | 1994-11-10 | The United States Of America, Represented By The | 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists |
| GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
| WO1995011681A1 (en) * | 1993-10-29 | 1995-05-04 | Merck & Co., Inc. | Human adenosine receptor antagonists |
| US5646156A (en) * | 1994-04-25 | 1997-07-08 | Merck & Co., Inc. | Inhibition of eosinophil activation through A3 adenosine receptor antagonism |
| US5922751A (en) | 1994-06-24 | 1999-07-13 | Euro-Celtique, S.A. | Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same |
| US5591776A (en) * | 1994-06-24 | 1997-01-07 | Euro-Celtique, S.A. | Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV |
| US6514949B1 (en) | 1994-07-11 | 2003-02-04 | University Of Virginia Patent Foundation | Method compositions for treating the inflammatory response |
| US6448235B1 (en) | 1994-07-11 | 2002-09-10 | University Of Virginia Patent Foundation | Method for treating restenosis with A2A adenosine receptor agonists |
| GB9415529D0 (en) * | 1994-08-01 | 1994-09-21 | Wellcome Found | Phenyl xanthine derivatives |
| ATE247116T1 (de) | 1994-12-13 | 2003-08-15 | Euro Celtique Sa | Arylthioxanthine |
| EP0799040B1 (en) * | 1994-12-13 | 2003-08-20 | Euroceltique S.A. | Trisubstituted thioxanthines |
| US6025361A (en) | 1994-12-13 | 2000-02-15 | Euro-Celtique, S.A. | Trisubstituted thioxanthines |
| US5733932A (en) * | 1995-01-06 | 1998-03-31 | The Picower Institute For Medical Research | Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions |
| US6268373B1 (en) | 1995-06-07 | 2001-07-31 | Euro-Celtique S.A. | Trisubstituted thioxanthines |
| US6166041A (en) | 1995-10-11 | 2000-12-26 | Euro-Celtique, S.A. | 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma |
| US6075016A (en) | 1996-04-10 | 2000-06-13 | Euro-Celtique S.A. | 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity |
| US6316423B1 (en) | 1996-04-10 | 2001-11-13 | The United States Of America As Represented By The Departmant Of Health And Human Services | Method of treating ischemic, hypoxic and anoxic brain damage |
| US5864037A (en) | 1996-06-06 | 1999-01-26 | Euro-Celtique, S.A. | Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity |
| US6294541B1 (en) | 1996-06-06 | 2001-09-25 | Euro-Celtique S.A. | Purine derivatives having phosphodiesterase IV inhibition activity |
| US5728560A (en) * | 1996-06-14 | 1998-03-17 | Enzon, Inc. | Method of treating CD4+ T cell lymphopenia in immuno-compromised patients |
| US5744473A (en) * | 1996-09-16 | 1998-04-28 | Euro-Celtique, S.A. | PDE IV inhibitors: "bis-compounds" |
| GB9703044D0 (en) | 1997-02-14 | 1997-04-02 | Glaxo Group Ltd | Phenyl xanthine esters and amides |
| US6063363A (en) * | 1997-05-27 | 2000-05-16 | Goodwin; Gary J | Treatment for upper respiratory tract infections with potassium salts |
| AU1723099A (en) | 1997-12-12 | 1999-07-05 | Euro-Celtique S.A. | 3-substituted adenines via2-thioxanthines |
| US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| US6303619B1 (en) * | 1998-03-12 | 2001-10-16 | University Of Virginia | Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors |
| GB9817623D0 (en) | 1998-08-13 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| US6319928B1 (en) | 1998-11-30 | 2001-11-20 | Euro-Celtique, S.A. | Purine derivatives having phosphodiesterase IV inhibition activity |
| US7427606B2 (en) * | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
| US7378400B2 (en) * | 1999-02-01 | 2008-05-27 | University Of Virginia Patent Foundation | Method to reduce an inflammatory response from arthritis |
| US7214665B2 (en) * | 2001-10-01 | 2007-05-08 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof |
| US6232297B1 (en) | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
| HUP0200938A2 (en) | 1999-04-02 | 2002-10-28 | Euro Celtique Sa | Purine derivatives having phosphodiesterase iv inhibition activity and medicaments containing them |
| US6545002B1 (en) | 1999-06-01 | 2003-04-08 | University Of Virginia Patent Foundation | Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors |
| US6322771B1 (en) | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
| US7253176B1 (en) * | 2000-05-04 | 2007-08-07 | K.U. Leuven Research & Development | Immunosuppressive effects of 8-substituted xanthine derivatives |
| US6670334B2 (en) | 2001-01-05 | 2003-12-30 | University Of Virginia Patent Foundation | Method and compositions for treating the inflammatory response |
| US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US20080318983A1 (en) * | 2001-11-09 | 2008-12-25 | Rao Kalla | A2b adenosine receptor antagonists |
| US7125993B2 (en) * | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US6977300B2 (en) * | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| EP1444233B1 (en) | 2001-11-09 | 2011-08-17 | Gilead Palo Alto, Inc. | A2b adenosine receptor antagonists |
| US20040072848A1 (en) * | 2002-02-26 | 2004-04-15 | Huber Brian E | Methods of treating irritable bowel syndrome and functional dyspepsia |
| CN1671716A (zh) * | 2002-06-12 | 2005-09-21 | 拜奥根Idec马萨诸塞公司 | 用腺苷受体拮抗剂治疗缺血再灌注损伤的方法 |
| US7202252B2 (en) * | 2003-02-19 | 2007-04-10 | Endacea, Inc. | A1 adenosine receptor antagonists |
| WO2004106337A1 (en) * | 2003-05-06 | 2004-12-09 | Cv Therapeutics, Inc. | Xanthine derivatives as a2b adenosine receptor antagonists |
| CA2528385C (en) * | 2003-06-06 | 2011-03-15 | Endacea, Inc. | A1 adenosine receptor antogonists |
| EP1778712B1 (en) * | 2004-08-02 | 2013-01-30 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
| WO2006028618A1 (en) * | 2004-08-02 | 2006-03-16 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
| US7442687B2 (en) * | 2004-08-02 | 2008-10-28 | The University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
| JP4929173B2 (ja) * | 2004-09-01 | 2012-05-09 | ギリアード・パロ・アルト・インコーポレイテッド | Ａ２ｂアデノシンレセプターアンタゴニストを使用する創傷治癒の方法 |
| WO2007092936A2 (en) * | 2006-02-08 | 2007-08-16 | University Of Virginia Patent Foundation | Method to treat gastric lesions |
| US8178509B2 (en) | 2006-02-10 | 2012-05-15 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
| US8188063B2 (en) | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
| US8193200B2 (en) | 2007-01-04 | 2012-06-05 | University Of Virginia Patent Foundation | Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease |
| US8058259B2 (en) * | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2602795A (en) | 1950-06-24 | 1952-07-08 | Searle & Co | Hydroxyalkyl alkyl derivatives of 5-nitroso-6-amino-1, 2, 3, 4-tetrahydro-2, 4-pyrimidinedione |
| US4452788A (en) * | 1982-04-21 | 1984-06-05 | Warner-Lambert Company | Substituted 8-phenylxanthines |
| US4593095A (en) * | 1983-02-18 | 1986-06-03 | The Johns Hopkins University | Xanthine derivatives |
| US4696932A (en) * | 1984-10-26 | 1987-09-29 | The United States Of America As Represented By The Department Of Health And Human Services | Biologically-active xanthine derivatives |
| US4612315A (en) * | 1984-10-26 | 1986-09-16 | The United States Of America As Represented By The Department Of Health And Human Services | Biologically-active 1,3-dipropyl-8-phenylxanthine derivatives |
| GB8510758D0 (en) * | 1985-04-27 | 1985-06-05 | Wellcome Found | Compounds |
| DE3522230A1 (de) * | 1985-06-21 | 1987-01-02 | Thomae Gmbh Dr K | Neue 2-arylimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
-
1985
- 1985-04-27 GB GB858510758A patent/GB8510758D0/en active Pending
-
1986
- 1986-04-23 IL IL78605A patent/IL78605A/xx unknown
- 1986-04-24 NZ NZ215948A patent/NZ215948A/xx unknown
- 1986-04-24 DK DK190486A patent/DK169271B1/da not_active IP Right Cessation
- 1986-04-24 PT PT82451A patent/PT82451B/pt unknown
- 1986-04-24 AU AU56707/86A patent/AU581507B2/en not_active Expired
- 1986-04-25 EP EP86303171A patent/EP0203721B1/en not_active Expired - Lifetime
- 1986-04-25 DE DE8686303171T patent/DE3685608T2/de not_active Expired - Lifetime
- 1986-04-25 JP JP61094957A patent/JPH0788381B2/ja not_active Expired - Lifetime
- 1986-04-25 GR GR861107A patent/GR861107B/el unknown
- 1986-04-25 NO NO861643A patent/NO861643L/no unknown
- 1986-04-25 AP APAP/P/1986/000036A patent/AP22A/en active
- 1986-04-25 HU HU861730A patent/HUT41027A/hu unknown
- 1986-04-25 FI FI861750A patent/FI861750A/fi not_active Application Discontinuation
- 1986-04-25 US US06/856,719 patent/US4879296A/en not_active Expired - Lifetime
- 1986-04-25 ZA ZA863132A patent/ZA863132B/xx unknown
- 1986-04-25 MC MC861834A patent/MC1743A1/xx unknown
- 1986-04-25 AT AT86303171T patent/ATE77088T1/de not_active IP Right Cessation
- 1986-04-25 CA CA000507576A patent/CA1286666C/en not_active Expired - Fee Related
- 1986-04-25 ES ES554380A patent/ES8800945A1/es not_active Expired
- 1986-04-25 KR KR1019860003211A patent/KR860008176A/ko not_active Application Discontinuation
- 1986-04-28 IE IE110486A patent/IE60022B1/en not_active IP Right Cessation
-
1989
- 1989-08-29 US US07/400,464 patent/US4981857A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US4879296A (en) | 1989-11-07 |
| GR861107B (en) | 1986-08-04 |
| DE3685608D1 (de) | 1992-07-16 |
| JPS6242986A (ja) | 1987-02-24 |
| MC1743A1 (fr) | 1987-02-26 |
| AU5670786A (en) | 1986-10-30 |
| HUT41027A (en) | 1987-03-30 |
| AP8600036A0 (en) | 1986-02-01 |
| AU581507B2 (en) | 1989-02-23 |
| CA1286666C (en) | 1991-07-23 |
| EP0203721B1 (en) | 1992-06-10 |
| PT82451A (en) | 1986-05-01 |
| NZ215948A (en) | 1989-10-27 |
| ES8800945A1 (es) | 1987-12-01 |
| IL78605A0 (en) | 1986-08-31 |
| IL78605A (en) | 1989-07-31 |
| FI861750A (fi) | 1986-10-28 |
| DE3685608T2 (de) | 1992-12-24 |
| EP0203721A3 (en) | 1988-06-08 |
| KR860008176A (ko) | 1986-11-12 |
| US4981857A (en) | 1991-01-01 |
| DK169271B1 (da) | 1994-09-26 |
| FI861750A0 (fi) | 1986-04-25 |
| ES554380A0 (es) | 1987-12-01 |
| JPH0788381B2 (ja) | 1995-09-27 |
| IE60022B1 (en) | 1994-05-18 |
| EP0203721A2 (en) | 1986-12-03 |
| ZA863132B (en) | 1987-12-30 |
| DK190486D0 (da) | 1986-04-24 |
| ATE77088T1 (de) | 1992-06-15 |
| PT82451B (pt) | 1988-11-30 |
| GB8510758D0 (en) | 1985-06-05 |
| DK190486A (da) | 1986-10-28 |
| IE861104L (en) | 1986-10-27 |
| AP22A (en) | 1988-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO861643L (no) | Nye 8-fenylxantiner og fremgangsmaate for deres fremstilling. | |
| US6743798B1 (en) | Substituted pyrazole derivatives condensed with six-membered heterocyclic rings | |
| DE60101158T2 (de) | 8-chinolinxanthin and 8-isochinolinxanthin derivate als pde 5 inhibitoren | |
| US6864253B2 (en) | Benzo[4,5]thieno[2,3-c]pyridine and Benzo[4,5]furo[2,3-c]pyridine Derivatives Useful as Inhibitors of Phosphodiesterase | |
| US4500525A (en) | Pharmacologically active pyrazolo/4,3-c/pyridines | |
| US6545000B1 (en) | [1,2,4]triazolo[1,5-c]pyrimidine derivatives | |
| BG99489A (bg) | Асиметрично заместен ксантини с аденозинантагонистични свойства, метод за тяхното получаване и междинни съединения за тази цел, приложение на тези съединения като фармакологични средства, фармацевтични смеси които ги съдържат и метод за тяхното получаване | |
| SE416810B (sv) | Forfarande for framstellning av xantinderivat med antiallergisk aktivitet | |
| JP3116230B2 (ja) | 三環式縮合ピリミジン誘導体 | |
| US6077841A (en) | 5-heterocyclyl pyrazolo[4,3-d]pyrimidin-7-ones for the treatment of male erectile dysfunction | |
| EP3700895B1 (en) | Polycyclic amides as muscarinic m1 receptor positive allosteric modulators | |
| CS262690B2 (en) | Process for preparing 1-/hydroxystyryl/-5h-2,3-benzodiazepines | |
| KR100195368B1 (ko) | 선택적인 아데노신 수용체 제제 및 이의 제조방법 | |
| JPS6187681A (ja) | １ｈ‐インドル‐３‐イルを含む１，３‐ジメチル‐１ｈ‐プリン‐２，６‐ジオン類、その製法および用途 | |
| US5015647A (en) | Method for treating viral infections | |
| US5017577A (en) | Methods for treating viral infection | |
| US4942143A (en) | Imidazothiadiazine derivatives, and their use as medicaments | |
| NO832964L (no) | Analogifremgangsmaate for fremstilling av aktive tieno-tiazol-derivater | |
| CZ284350B6 (cs) | Deriváty l,3-dihydro-2H-pyrrolo[2,3-b]chinolin-2-onu, způsob a meziprodukty pro jejich výrobu, farmaceutické prostředky na jejich bázi a způsob jejich výroby | |
| US20040038996A1 (en) | 8-Quinolinxanthine and 8-isoquinolinxant hine derivatives as PDE 5 inhibitors | |
| US7291627B2 (en) | Dihydroimidazo[5.1-a]-beta-carboline derivatives, method for their preparation, and their application as a drug | |
| IE780310L (en) | Heterocyclopyrimidines | |
| CS41991A3 (en) | 2,4,8-trisubstituted-3h,6h-1,4,5a,8a-tetraazaacenaphthylene-3,5-(4h)-diones and,4,8-trisubstituted-4,5-dihydro-5-thioxo-3h,6h,1,4,5a, 8a-tetraazaacenaphthylene-3-ons | |
| NO812963L (no) | Analogifremgangsmaate for fremstilling av nye pyraziner | |
| US3466290A (en) | 9,10-dihydro-4h-benzo(4,5)cyclohepta(1,2-b)thiophene ethers |